Showing 33,521 - 33,540 results of 35,706 for search '"laboratory"', query time: 0.15s Refine Results
  1. 33521
  2. 33522
  3. 33523
  4. 33524
  5. 33525
  6. 33526

    The potential utility of synovial C-reactive protein, interleukin-6, and presepsin in diagnostics of periprosthetic joint infection by Lyudmila V. Lyubimova, Svetlana I. Pavlova, Nikolay S. Nikolaev, Evgeniy A. Lyubimov, Nadezhda N. Pchelova, Vladimir Y. Emelianov

    Published 2024-12-01
    “…ROC analysis, sensitivity, specificity, accuracy, and threshold values were determined for laboratory data. Results. The highest diagnostic accuracy in distinguishing between PJI and aseptic loosening was observed in the leukocyte count in synovial fluid (AUC 0.928; 95% CI: 0.837-0.977, p0.0001). …”
    Get full text
    Article
  7. 33527
  8. 33528
  9. 33529

    Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort by Conti Fabrizio, Ceccarelli Fulvia, Perricone Carlo, Massaro Laura, Marocchi Elisa, Miranda Francesca, Spinelli Francesca Romana, Truglia Simona, Alessandri Cristiano, Valesini Guido

    Published 2015-01-01
    “…We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the anti-dsDNA status. …”
    Get full text
    Article
  10. 33530
  11. 33531
  12. 33532
  13. 33533
  14. 33534
  15. 33535
  16. 33536

    The Spectrum of Pulmonary Disease in Patients with HIV Infection by Julio Sg Montaner, Leila Spour, Carlos Zala

    Published 1994-01-01
    “…The same can be said of radiographic findings as well as laboratory and physiological abnormalities. Of note, the lactate dehydrogenase (LDH) serum level has proved to be extremely useful in ruling out PCP. …”
    Get full text
    Article
  17. 33537

    A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults by Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin

    Published 2025-01-01
    “…Treatment emergent adverse events (AEs), clinical laboratory data, and vital signs were evaluated. Overall, 24 participants were randomized to nirsevimab (n = 18) or placebo (n = 6). …”
    Get full text
    Article
  18. 33538
  19. 33539
  20. 33540